|
1) Austen KF. Doing what I like. Annu Rev Immunol. 2008; 26: 1-28
|
|
|
|
2) Peters-Golden M, Henderson WR Jr. Leuko-trienes. N Engl J Med. 2007; 357: 1841-54
|
|
|
|
|
|
3) Ogawa Y, Calhoun WJ. The role of leukotrienes in airway inflammation. J Allergy Clin Immunol. 2006; 118: 789-98
|
|
|
|
|
|
4) Boyce JA. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev. 2007; 217: 168-85
|
|
|
|
|
|
5) Currie GP, McLaughlin K. The expanding role of leukotriene receptor antagonists in chronic asthma. Ann Allergy Asthma Immunol. 2006; 97: 731-41
|
|
|
|
|
|
6) Iikura M, Suzukawa M, Yamaguchi M, et al. 5-lipoxygenase products regulate basophil functions. J Allergy Clin Immunol. 2005; 116: 578-85
|
|
|
|
|
|
7) Okuno T, Iizuka Y, Okazaki H, et al. 12(S)-hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med. 2008; 205: 759-66
|
|
|
|
|
|
8) Goetzl EJ. Lipid mediators of hypersensitivity and inflammation. In: Adkinson NF Jr, et al. Editors. Middleton's Allergy: Principles and Practice. 6th edition. St. Louis: Mosby; 2003. p. 213-30
|
|
|
|
|
|
9) Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Ann Intern Med. 1999; 130: 487-95
|
|
|
|
|
|
10) Wenzel SE. Antileukotriene therapy in asthma. In: Adkinson NF Jr, et al. Editors. Middleton's Allergy: Principles and Practice. 6th edition. Mosby; 2003. p. 943-56
|
|
|
|
|
|
11) 東 憲孝, 東 愛, 三田晴久, 他. NSAIDs過敏喘息の病態の解明の現状. アレルギーの臨床. 2007; 27: 194-8
|
|
|
|
|
12) Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007; 175: 783-90
|
|
|
|
|
|
13) Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006; 27: 495-503
|
|
|
|
|
|
14) Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005; 171: 315-22
|
|
|
|
|
|
15) Johnston NW, Mandhane PJ, Dai J, et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics. 2007; 120: e702-12
|
|
|
|
|
|
16) Robertson CF, Price D, Henry R, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med. 2007; 175: 323-9
|
|
|
|
|
|
17) Okunishi K, Dohi M, Nakagome K, et al. A novel role of cysteinyl leukotrienes to promote dendritic cell activation in the antigen-induced immune responses in the lung. J Immunol. 2004; 173: 6393-402
|
|
|
|
|
|
18) Machida I, Matsuse H, Kondo Y, et al. Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma. J Immunol. 2004; 172: 1833-8
|
|
|
|
|
|
19) Henderson WR Jr, Chiang GK, Tien YT, et al. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med. 2006; 173: 718-28
|
|
|
|
|
|
20) Kelly MM, Chakir J, Vethanayagam D, et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest. 2006; 130: 741-53
|
|
|
|
|
|
21) Kato Y, Fujisawa T, Nishimori H, et al. Leukotriene D4 induces production of trans-forming growth factor-beta1 by eosinophils. Int Arch Allergy Immunol. 2005; 137: S17-20
|
|
|
|
|
|
22) 浅野浩一郎. 抗ロイコトリエン薬. 成人病と生活習慣病. 2008; 38: 303-6
|
|
|
|
|
|
23) Lee KS, Kim SR, Park HS, et al. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J Allergy Clin Immunol. 2004; 114: 1093-9
|
|
|
|
|
|
24) Moos MP, Mewburn JD, Kan FW, et al. Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB J. 2008 Sep 8. [Epub ahead of print]
|
|
|
|
|
|
25) Terawaki K, Yokomizo T, Nagase T, et al. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol. 2005; 175: 4217-25
|
|
|
|
|
|
26) Gelfand EW, Dakhama A. CD8＋ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. J Allergy Clin Immunol. 2006; 117: 577-82
|
|
|
|
|
|
27) Miyahara N, Miyahara S, Takeda K, et al. Role of the LTB4/BLT1 pathway in allergen-induced airway hyperresponsiveness and inflammation. Allergol Int. 2006; 55: 91-7
|
|
|
|
|
28) Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol. 2007; 119: 1055-62
|
|
|
|
|
|
29) Evans DJ, Barnes PJ, Spaethe SM, et al. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax. 1996; 51: 1178-84
|
|
|
|
|
|
30) Crooks SW, Bayley DL, Hill SL, et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J. 2000; 15: 274-80
|
|
|
|
|
|
31) Beeh KM, Kornmann O, Buhl R, et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest. 2003; 123: 1240-7
|
|
|
|
|
|
32) Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J Allergy Clin Immunol. 2007; 120: 1269-75
|
|
|
|
|
|
33) Nagase T, Uozumi N, Ishii S, et al. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nat Immunol. 2000; 1: 42-6
|
|
|
|
|
|
34) Nagase T, Uozumi N, Ishii S, et al. A pivotal role of cytosolic phospholipase A2 in bleomycin-induced pulmonary fibrosis. Nat Med. 2002; 8: 480-4
|
|
|
|
|
|
35) Huang SK, Peters-Golden M. Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time？ Chest. 2008; 133: 1442-50
|
|
|
|
|
|
36) Izumo T, Kondo M, Nagai A. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci. 2007; 80: 1882-6
|
|
|
|
|
|
37) Balfour-Lynn IM. Anti-inflammatory approaches to cystic fibrosis airways disease. Curr Opin Pulm Med. 2007; 13: 522-8
|
|
|
|
|
|
38) Bailie MB, Standiford TJ, Laichalk LL, et al. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J Immunol. 1996; 157: 5221-4
|
|
|
|
|
|
39) Mancuso P, Nana-Sinkam P, Peters-Golden M. Leukotriene B4 augments neutrophil phago-cytosis of Klebsiella pneumoniae. Infect Immun. 2001; 69: 2011-6
|
|
|
|
|